8-K 1 amic_8k-10072010.htm ADVANCED MEDICAL ISOTOPE 8K 10-07-2010 amic_8k-10072010.htm
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
Current Report
 
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): October 7, 2010
 
 
ADVANCED MEDICAL ISOTOPE CORPORATION
(Name of registrant as specified in its charter)

Delaware
0-53497
80-0138937
(State or other jurisdiction of
Incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification Number)
     
8131 W. Grandridge Blvd.  Suite 101, Kennewick WA 99336
  
99336
(Address of principal executive offices)
  
(Zip Code)

Registrant’s telephone number, including area code: (509) 736-4000
 
N/A
(Former name or former address, if changed since last report)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
1
 
 

 
 
Item 8.01 Other Events
 
The Company has executed of an exclusive world-wide license for patented technology for a proprietary brachytherapy seed with a fast-dissolving matrix for optimized delivery of radionuclides to cancer tissue.
 
The resorbable seed provides controlled delivery of insoluble yttrium-90 microspheres. The new seed is a joint invention by radiochemists and medical physicists at Battelle in Richland, Washington, and pharmaceutical chemists at the University of Utah in Salt Lake City, Utah.
 
 
 
Item 9.01 Financial Statements and Exhibits.
 
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
ADVANCED MEDICAL ISOTOPE CORPORATION
  
       
Date: October 8, 2010
By:
/s/   James C. Katzaroff
  
 
Name:
James C. Katzaroff 
  
 
Title:
Chairman and Chief Executive Officer 
  
       

 
 
 
 
 
 
 
 
 
 
2